FOXO majority stockholder approves reverse stock split for potential Nasdaq/NYSE American uplisting

FOXO TECHNOLOGIES INC.

On Aug 13, 2026, Rennova Health (controlled by CEO) approved reverse split amendment via written consent.
Ratio range 1:50 to 1:1,000; exact ratio set by board solely to facilitate uplisting to Nasdaq or NYSE American.
Record date Aug 13, 2026; majority stockholder holds ~99.12% of voting rights.
Reverse split effective no earlier than 20 days after mailing definitive Schedule 14C; FINRA notice required.
Preliminary Schedule 14C filed Aug 14, 2026; board authorized split only for uplisting application.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.